There is broad acceptance in both the research and clinical communities that the age of personalized medicine is rapidly approaching. Numerous examples of biomarkers (and tests based on those biomarkers) have been shown to be relevant to clinically important phenotypes. Sequenom, Inc. is at the forefront of this molecular medicine revolution. The company provides genetic analysis instrumentation and reagents to the clinical and research communities. These products are being used for clinical validation of relevant biomarkers as well as for development of diagnostic tests based on those biomarkers.